PLYMOUTH MEETING, Pa., Oct. 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO Abstract Title: Reduction in Surgical In ...

PLYMOUTH MEETING, Pa., Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference: World Congress of Electroporation Oral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIO Abstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies emplo ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operato ...

Clinical Trials and Regulatory Updates - INO-3107 BLA submission delayed to mid-2025 due to manufacturing issues with the single-use disposable administration component of the CELLECTRA® device[2][3] - INO-3107 designated as an innovative medicine under the U.K.'s Innovative Licensing and Access Pathway (ILAP) and received Advanced Therapy Medicinal Product (ATMP) Certification from the European Medicines Agency[3] - INO-3112 Phase 3 trial design submitted to European regulatory authorities, with plans to investigate INO-3112 in combination with LOQTORZI for oropharyngeal squamous cell carcinoma (OPSCC)[4] - INO-4201 Phase 2/3 clinical trial protocol for Ebola booster expected to be submitted to the FDA in Q3 2024[5] Financial Performance and Cash Position - Cash, cash equivalents, and short-term investments totaled $110.4 million as of June 30, 2024, compared to $145.3 million as of December 31, 2023[7] - R&D expenses for Q2 2024 were $23.1 million, a slight decrease from $23.7 million in Q2 2023[7] - G&A expenses for Q2 2024 were $10.2 million, down from $13.5 million in Q2 2023[7] - Net loss for Q2 2024 was $32.2 million, or $1.19 per share, compared to a net loss of $35.5 million, or $1.61 per share, in Q2 2023[7] - INOVIO estimates its cash runway to extend into Q3 2025, with an operational net cash burn estimate of approximately $28 million for Q3 2024[9] - Cash and cash equivalents increased to $34,392,404 as of June 30, 2024, compared to $14,310,862 as of December 31, 2023[14] - Short-term investments decreased to $76,029,116 as of June 30, 2024, from $130,982,913 as of December 31, 2023[14] - Total current assets decreased to $117,561,045 as of June 30, 2024, from $153,113,100 as of December 31, 2023[14] - Total liabilities decreased to $37,057,996 as of June 30, 2024, from $53,602,294 as of December 31, 2023[14] - Revenue from collaborative arrangements and other contracts for the six months ended June 30, 2024, was $100,762, compared to $340,914 for the same period in 2023[15] - Research and development expenses for the six months ended June 30, 2024, were $44,001,307, compared to $53,920,481 for the same period in 2023[15] - General and administrative expenses for the six months ended June 30, 2024, were $20,781,337, compared to $27,413,708 for the same period in 2023[15] - Net loss for the six months ended June 30, 2024, was $(62,706,969), compared to $(76,183,850) for the same period in 2023[15] - Basic and diluted net loss per share for the six months ended June 30, 2024, was $(2.48), compared to $(3.50) for the same period in 2023[15] - Weighted average number of common shares used to compute net loss per share for the six months ended June 30, 2024, was 25,244,657, compared to 21,784,343 for the same period in 2023[15] Leadership and Organizational Updates - Steve Egge appointed as Chief Commercial Officer to lead commercial strategy and operations, bringing extensive experience in HPV, immunology, and rare diseases[6]

PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments. "We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-------------------------------- ...

"This latest regulatory achievement further validates our efforts to bring INO-3107 to RRP patients around the world and shows that our cross functional development team is meeting the highest of standards in pursuit of that goal," said Cheryl Elder, INOVIO's Senior Vice President of Regulatory Affairs. "We're pleased to receive confirmation that our development efforts in Europe continue to make progress." INO-3107 is designed to elicit an antigen-specific T cell response against both HPV-6 and HPV-11 prot ...

RRP is a rare degenerative disease that causes small growths (papillomas) in the respiratory tract. Generally, non-cancerous papillomas can cause severe and life-threatening airway obstruction and respiratory complications. Inovio believes that the Innovation Passport designation grant further bolsters the potential of INO-3107 to "transform" the treatment paradigm for RRP patients. The company, however, plans to initiate a confirmatory study of INO-3107 for RRP before submitting the BLA to the FDA. Apart f ...

Inovio Pharmaceuticals (INO) shares rallied 19% in the last trading session to close at $11.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.1% loss over the past four weeks. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price mo ...

"The U.K. Innovation Passport designation is yet another recognition of the promise of INO-3107 to potentially transform the treatment paradigm for RRP patients," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We are honored to receive this designation, which offers us enhanced access to regulators and development tools that could accelerate the timeline for achieving U.K. regulatory approval of INO-3107. We look forward to continuing our discussions with the ILAP partners as we ...